TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03921710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPA-IVM
Description: Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-IVM
Description: Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
Study: NCT03561857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy
Description: The study is divided in 2 parts.~1. Ex vivo study~   * Prostate specimens will be stained using Fluorescein~  * Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~2. In vivo study~   * Intravenous injection of contrast agent~  * pCLE imaging every 5mm of the NVB dissection zone.
Study: NCT00353743

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline plus metronidazole
Description: doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
Study: NCT00393679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amodiaquine-artesunate (ASAQ)
Description: A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHAPQ)
Description: DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Description: Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)
Description: Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008.
Study: NCT03592615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal refractive surgery
Description: Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
Study: NCT00966706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given systemically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given systemically
Study: NCT00874393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine
Study: NCT02015728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
Study: NCT00874393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infusion Placebo
Description: Dextrose (D5W)
Study: NCT02957734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation of severely worn dentitions
Description: Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
Study: NCT00195039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
Description: Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min.
Study: NCT00874393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion Placebo
Description: Dextrose (D5W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syringe Placebo
Description: Normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syringe Placebo
Description: Normal saline
Study: NCT01855672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of the Occipital Nerves
Description: Electrical stimulation of the occipital nerves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of the Occipital Nerves
Description: Electrical stimulation of the occipital nerves.
Study: NCT00312546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90 mg subcutaneously twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90 mg subcutaneously twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90 mg subcutaneously twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: 500 to 750 mg, taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: 500 to 750 mg, taken orally twice daily
Study: NCT03850847

Intervention type: OTHER
Intervention: Step 1: Semi-structured Interviews
Description: 1. Cover SDMs' experience around:~   * withdrawal of life sustaining therapies~  * organ donation among those who were approached (including with the medical team and the organ donation organisation)~  * understanding of the situation~  * views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~2. Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached).

Intervention type: OTHER
Intervention: Step 2: National Telephone Survey
Description: Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
Study: NCT02287571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derotation splint
Description: This group is the actual intervention group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: elastic bandage
Description: This group is the routine treatment (control) valid in the clinical practice.
Study: NCT02707302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iodophor-impregnated adhesive drapes group
Description: Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iodophor-free adhesive drapes group
Description: Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
Study: NCT04168450

Intervention type: OTHER
Group type: OTHER
Intervention: WiSAT System, Passive Feedback
Description: The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.

Intervention type: OTHER
Group type: OTHER
Intervention: WiSAT System, Active Feedback
Description: The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
Study: NCT00003996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01599221

Intervention type: DEVICE
Intervention: EBA2
Description: Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
Study: NCT02015728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a broad-spectrum kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is an mTOR pathway inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib is a broad spectrum SRC inhibitor.
Study: NCT00980252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
Study: NCT04032015

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Device used to administer electromagnetic fields to the brain to alter connectivity patterns

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Device used to administer electromagnetic fields to the brain to alter connectivity patterns
Study: NCT03304405

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait Analysis
Description: All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
Study: NCT00995917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin K acupoint injection
Description: Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline Injection
Description: Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
Study: NCT02950909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static exercise for emphasized neck extensors
Description: Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic exercise for emphasized neck extensors
Description: The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static exercise for general neck extensors
Description: Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic exercise for general neck extensors
Description: . The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
Study: NCT04146350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV+/-Cat
Description: pars plana vitrectomy+/-cataract

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV+/-Cat+Gas
Description: pars plana vitrectomy+/-cataract+gas tamponade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV+ILM+/-Cat+/-Gas
Description: pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV+ILM+/-Cat+/-Oil
Description: pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSR
Description: posterior scleral reinforcement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）
Description: posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gas
Description: gas tamponade alone
Study: NCT01407666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral blocks
Description: use bilateral thoracic paravertebral blocks for pain control
Study: NCT00795236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
Study: NCT00465088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER/Simvastatin Tablets
Description: Up to 2000 mg/40 mg at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 40 mg at bedtime
Study: NCT03142984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic Products
Description: Phase 1:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)
Study: NCT01005498

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate - high fat diet
Description: The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate - low fat diet
Description: The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
Study: NCT00226811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
Study: NCT03468361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Product Petroselinum crispum (Parsley)
Description: Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily.
Study: NCT03507205

Intervention type: DEVICE
Intervention: Biomatrix; Biomatrix Flex; Nobori
Description: Biodegradable polymer-coated biolimus-eluting stents
Study: NCT02312245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT06034444

Intervention type: OTHER
Intervention: interRAI LTCF
Description: Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
Study: NCT02367248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deferoxamine
Description: Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xingnaojing injection
Description: Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
Study: NCT01346722

Intervention type: OTHER
Group type: OTHER
Intervention: Diet-ZnBfR
Description: zinc biofortified rice-based diet

Intervention type: OTHER
Group type: OTHER
Intervention: Diet- CR
Description: conventional rice-based diet

Intervention type: OTHER
Group type: OTHER
Intervention: Diet-ZnBfR
Description: zinc biofortified rice-based diet

Intervention type: OTHER
Group type: OTHER
Intervention: CR + Zn
Description: conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
Study: NCT01768585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Please see description of Intervention Arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02571959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and clavulanic acid
Description: Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and clavulanic acid
Description: Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
Study: NCT01354080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage based on the tensegrity rule
Description: The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: massage - classical abdominal
Description: The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)